Precision Medicine Quarterly

Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan

2022-01-27T19:53:51-05:00January 27th, 2022|

Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory [...]

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

2022-01-27T19:47:21-05:00January 27th, 2022|

Lifebit announced a long-term partnership where Lifebit's technology, Lifebit CloudOS, will power a cloud-based Trusted Research Environment (TRE) to serve as the scalable and secure data management and analysis platform for researchers at the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC). As one of the leading UK biomedical research organisations, [...]

Active Motif Incorporated Announces the Acquisition of Amaryllis Nucleics and their proprietary RNASeq workflow

2022-01-27T19:43:42-05:00January 27th, 2022|

Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has purchased Amaryllis Nucleics, a Bay Area-based start-up company focused on proprietary RNA Sequencing methods. Amaryllis Nucleics provides Active Motif with a streamlined, low-cost library preparation method to perform high-efficiency RNA sequencing using their intellectual [...]

Flatiron Health Announces RWD Partnership with Japan’s NCCHE

2022-01-27T19:41:34-05:00January 27th, 2022|

Flatiron Health® announced a partnership with Japan’s National Cancer Center Hospital East (NCCHE) to build a real-world database of patients with gastro-intestinal cancers. “Insights from Flatiron’s U.S.-derived real-world data have brought important treatment alternatives to patients with cancer around the world,” said Carolyn Starrett, Flatiron CEO. “Adding more patient experiences into the evidence that [...]

PGDx Announces an Updated Medicare Reimbursement Rate for the elio™ tissue complete Test

2022-01-27T09:26:05-05:00January 27th, 2022|

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio™ tissue complete. The Centers for Medicare & Medicaid Services (CMS) finalized a national reimbursement rate of $2,919.60 for the PLA code (0250U) that PGDx obtained [...]

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer

2022-01-19T19:14:56-05:00January 19th, 2022|

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into two clinical trial collaboration and supply agreements with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of Gilead’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy) and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first-line metastatic non-small [...]

Paige Announces Executive Leadership Appointments

2022-01-19T19:10:10-05:00January 19th, 2022|

Paige, the global leader in AI-based diagnostic software in pathology, has announced that it has appointed Andy Moye, Ph.D., as Chief Executive Officer and Jill Stefanelli, Ph.D., as President and Chief Business Officer. Dr. Moye most recently served as Chief Commercial Officer at Paige, where he led the company’s clinical sales and commercial strategy, including [...]

M2GEN Expands Leadership Team, Appointing Daniel Elgort, Ph.D. as Chief Data and Analytics Officer and May Yoon as Chief People Officer

2022-01-19T19:06:16-05:00January 19th, 2022|

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry leading data and analytics, today announced that it has expanded its executive team with the appointments of Daniel Elgort, Ph.D., as Chief Data and Analytics Officer and May Yoon as Chief People Officer. The two appointments strengthen M2GEN's commitment to deliver differentiated analytics [...]

Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership

2022-01-19T19:03:43-05:00January 19th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) outlined upcoming portfolio milestones that are anticipated to extend its position as a leading precision therapy company. "With two precision therapies expanding their global reach across multiple approved indications, four INDs filed from our portfolio in 2021, and a range of clinical data inflection points anticipated over the next [...]

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

2022-01-19T18:57:09-05:00January 19th, 2022|

Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a multinational biopharmaceutical and diagnostics company, announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc. (“GeneDx”), a leader in genomic testing and analysis, from OPKO. The acquisition [...]

Go to Top